{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:03:18Z","timestamp":1767988998883,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":278,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5T32CA009357-39"],"award-info":[{"award-number":["5T32CA009357-39"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100352","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T12:24:34Z","timestamp":1665145474000},"page":"100352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation\u2013A single institution experience"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-2022","authenticated-orcid":false,"given":"Radhika","family":"Takiar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Foucar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-8948","authenticated-orcid":false,"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Benitez-Colon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4975-1684","authenticated-orcid":false,"given":"Patrick W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale L.","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2022.100352_bib0001","unstructured":"National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia (Version 2.2020). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bone.pdf. Accessed November 25th, 2020."},{"issue":"11","key":"10.1016\/j.lrr.2022.100352_bib0002","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult acute lymphoblastic leukemia","volume":"91","author":"Paul","year":"2016","journal-title":"Mayo Clinic. Proc."},{"issue":"11","key":"10.1016\/j.lrr.2022.100352_bib0003","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2022.100352_bib0004","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.lrr.2022.100352_bib0005","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","article-title":"Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group","volume":"112","author":"Burmeister","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lrr.2022.100352_bib0006","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.seminhematol.2006.01.007","article-title":"Management of acute lymphoblastic leukemia in older patients","volume":"43","author":"Larson","year":"2006","journal-title":"Semin. Hematol."},{"issue":"11","key":"10.1016\/j.lrr.2022.100352_bib0007","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.lrr.2022.100352_bib0008","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2022.100352_bib0009","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0889-8588(05)70192-1","article-title":"The hyper-CVAD regimen in adult acute lymphocytic leukemia","volume":"14","author":"Garcia-Manero","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.lrr.2022.100352_bib0010","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2022.100352_bib0011","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.lrr.2022.100352_bib0012","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.lrr.2022.100352_bib0013","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.lrr.2022.100352_bib0014","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lrr.2022.100352_bib0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"Liu-Dumlao","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.lrr.2022.100352_bib0016","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2022.100352_bib0017","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/sj.leu.2401589","article-title":"Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission","volume":"13","author":"Snyder","year":"1999","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.lrr.2022.100352_bib0018","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2022.100352_bib0019","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.beha.2016.10.009","article-title":"Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?","volume":"29","author":"Litzow","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"4","key":"10.1016\/j.lrr.2022.100352_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","article-title":"Efficacy of Ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"18","author":"Jabbour","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"23","key":"10.1016\/j.lrr.2022.100352_bib0021","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.81.81","article-title":"Multicenter total therapy gimema LAL 1509 protocol for De Novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. updated results and refined genetic-based prognostic stratification","volume":"126","author":"Chiaretti","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2022.100352_bib0022","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.2015.124016","article-title":"Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia","volume":"100","author":"Leoni","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lrr.2022.100352_bib0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428190701713689","article-title":"Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"49","author":"Li","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.lrr.2022.100352_bib0024","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lrr.2022.100352_bib0025","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"63","key":"10.1016\/j.lrr.2022.100352_bib0026","doi-asserted-by":"crossref","first-page":"107022","DOI":"10.18632\/oncotarget.22206","article-title":"Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lrr.2022.100352_bib0027","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.lrr.2022.100352_bib0028","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.lrr.2022.100352_bib0029","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2022.100352_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1179\/1607845412Y.0000000052","article-title":"The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Zhang","year":"2013","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.lrr.2022.100352_bib0031","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"suppl 5","key":"10.1016\/j.lrr.2022.100352_bib0032","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"ESMO guidelines committee. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lrr.2022.100352_bib0033","unstructured":"Center for international blood & marrow transplant research. forms instruction manual. ALL Response Criteria http:\/\/www.cibmtr.org\/manuals\/fim\/1\/en\/topic\/all-response-criteria."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:18Z","timestamp":1761959358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":33,"alternative-id":["S2213048922000644"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100352","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation\u2013A single institution experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100352"}}